Pembrolizumab vs chemotherapy in PD-L1+ NSCLC
Reck M, Rodríguez-Abreu D, Robinson AG
New England Journal of Medicine · 2016
This randomized controlled trial evaluates the intervention under study in relation to the primary clinical outcome. Includes 305 participants. Evidence level: Ia.
循证研究：Pembrolizumab治疗PD-L1+ NSCLC
Key facts at a glance
- DOI
- 10.1056/NEJMoa1507643
- PMID
- 27648635
- Journal
- New England Journal of Medicine
- Year
- 2016
- Study type
- rct
- Evidence level
- Ia
- Sample size
- 305
- Intervention
- Pembrolizumab vs 含铂化疗
- Primary outcome
- 无进展生存期 (PFS)
- Open access
- false
Study Overview
This randomized controlled trial enrolled 305 participants and examined the primary clinical outcome.
Key Findings
Results regarding the primary clinical outcome are presented.
Clinical Conclusions
See original publication for detailed findings. Evidence level: Ia.
Abstract
"This randomized controlled trial enrolled 305 participants, investigating the effects of Pembrolizumab vs 含铂化疗 on 无进展生存期 (PFS).
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed October 18, 2026. · Read our editorial policy